Treatment Considerations for CLL

 

K

MURANO Phase 3 Trial: Enduring Undetectable MRD and Updated Outcomes in R/R CLL After Fixed-Duration Venetoclax-Rituximab

By Kirollos Hanna
198 views
December 21, 2022
0 Comments
Login to view comments. Click here to Login
Treatment Considerations for CLL
08:57
Carsten Utoft Niemann

Fixed-Duration Therapy in CLL: Is It a Safer Option for Patients?

09:46
Christopher Pleyer

Venetoclax + Obinutuzumab for Previously Untreated CLL: Latest Learn…

19:42
Jacqueline Barrientos

Considerations for Sequencing Treatments in CLL

14:05
The University of Kansas Cancer Center

Five-Year Updates on Venetoclax + Obinutuzumab for Previously Untrea…

Feat. M. Hoffmann
33:21
Moffitt Cancer Center

MRD in CLL/SLL: Is It Ready for Prime Time?

Feat. J. Sandoval-Sus
27:08
Tara Graff

Updates on Venetoclax in CLL

09:45
ASH 2022 Conference Coverage

ASH 2022 Treatment of CLL-Associated Autoimmune Cytopenias and Outco…

Feat. K. Rogers
11:52
ASH 2022 Conference Coverage

ASH 2022 Real-World OS and TTNT by 1L Therapy (BTKi and BCL2i) in Pa…

Feat. W. Archibald, C. Wang
07:24
Kirollos Hanna

MURANO Phase 3 Trial: Enduring Undetectable MRD and Updated Outcomes…

14:12
Northwell Health

Treatment Considerations for Patients With CLL Who Are Elderly or Ha…

Feat. J. Rhodes
14:31
Lydia Scarfò

Upcoming BTKi Therapies in CLL

11:07
SOHO 2022 Tenth Annual Meeting

SOHO 2022: BCL2i in CLL

Feat. A. Chanan-Khan
20:55
ERIC 2022 - European Research Initiative on CLL - ERIC

The Tumor: Biomarker-Guided Treatment in CLL

Feat. O. Al-Sawaf
21:28
ERIC 2022 - European Research Initiative on CLL - ERIC

Combined Inhibition of Signaling and Anti-Apoptotic Pathways in CLL

Feat. P. Hillmen
06:33
Arnon Kater

Updates From a MRD Model From the MURANO Trial: CLL Clonal Growth Ra…